MAIA Biotechnology announces new partial response in Phase 2 THIO-101 trial

MAIA Biotechnology (MAIA) announced a new partial response was identified in a patient after 20 months of treatment in its Phase 2 THIO-101 clinical trial evaluating ateganosine, sequenced with Regeneron’s immune checkpoint inhibitor cemiplimab in patients with advanced non-small cell lung cancer who are resistant to immune therapy and chemotherapy. A partial response is defined as a decrease in tumor size of at least 30%. “The patient remained on treatment and we observed stable disease for more than twenty months before the partial response was identified, highlighting the efficacy, safety and low toxicity of the treatment. Extended-term responses like this are not often seen in heavily pretreated patients in hard-to-treat diseases such as NSCLC, where the prognosis for the advanced-stage of the disease is typically poor,” said CEO Vlad Vitoc. “We confirmed this response with a second scan, and we are highly confident that ateganosine could become an outstanding therapeutic alternative for third-line NSCLC patients.” THIO-101 third line data cutoff from May 15, showed median overall survival of 17.8 months for the 22 NSCLC patients who received at least one dose of ateganosine in parts A and B of the trial. At the data cutoff, the patient with the longest survival in the trial had completed 32 cycles of therapy and had 24.3 months survival. Studies of standard-of-care chemotherapy treatments for NSCLC in a similar setting have shown OS of 5 to 6 months.